Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Rating of "Hold" from Analysts

Key Points

• Halozyme Therapeutics has received an average rating of "Hold" from thirteen analysts, with one sell rating, six hold ratings, and six buy ratings.
• Analysts have set a twelve-month target price for the stock at $73.00, with recent price targets ranging from $60.00 to $90.00 by different firms.
• The company reported a 40.8% year-over-year increase in revenue for the last quarter, achieving $325.72 million against expectations of $282.66 million.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been given an average rating of "Hold" by the thirteen ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $73.00.

Several research analysts have issued reports on HALO shares. HC Wainwright increased their target price on shares of Halozyme Therapeutics from $85.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, October 2nd. JPMorgan Chase & Co. increased their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Zacks Research cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, October 6th. Leerink Partners upgraded shares of Halozyme Therapeutics from an "underperform" rating to a "market perform" rating and set a $70.00 target price on the stock in a report on Tuesday. Finally, Wall Street Zen cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th.

Halozyme Therapeutics Trading Up 2.0%

NASDAQ HALO opened at $66.65 on Wednesday. The company's 50-day moving average price is $71.30 and its 200-day moving average price is $62.01. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The stock has a market cap of $7.80 billion, a PE ratio of 15.25, a PEG ratio of 0.35 and a beta of 1.16. Halozyme Therapeutics has a 12 month low of $42.01 and a 12 month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business's revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities research analysts forecast that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 20,000 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the sale, the chief financial officer directly owned 24,306 shares of the company's stock, valued at approximately $1,840,207.26. This represents a 45.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the sale, the chief executive officer directly owned 733,719 shares of the company's stock, valued at approximately $55,285,726.65. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 108,227 shares of company stock worth $7,779,595 in the last three months. Corporate insiders own 2.90% of the company's stock.

Institutional Trading of Halozyme Therapeutics

Hedge funds have recently modified their holdings of the company. Wealth Preservation Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the first quarter valued at about $32,000. SVB Wealth LLC purchased a new stake in shares of Halozyme Therapeutics during the first quarter valued at about $33,000. Bessemer Group Inc. lifted its position in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of Halozyme Therapeutics during the second quarter valued at about $32,000. Finally, Employees Retirement System of Texas purchased a new stake in shares of Halozyme Therapeutics during the second quarter valued at about $34,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.